The 2-Minute Rule for QST4
The key finish point was the safety and tolerability of sifalimumab. Treatment-emergent adverse situations (AEs) and severe AEs (SAEs) and their severity, consequence, and any romance for the study medication had been recorded by the investigator all over the research. AEs have been regarded as more likely to be associated with research medication